Table 4. Individual data of all study patients (n = 9).
| Case | Age (years) | Sex | Smoking status | Types of EGFR mutation | Prevoius treatmet lines before nivolumab | EGFR-TKIs | PD-L1 expression | No. of CD4+ T cells (/mm2) | N0. of CD8+ T cells (/mm2) | No. of Foxp3+ T cells (/mm2) | PS | NLR | Response to nivolumab | PFS (days) | OS (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 37 | F | Never | 19del. +T790M | 5 | G→E→A | 0% | 2882 | 156 | 44 | 1 | 2.4 | PD | 19 | 469 |
| 2 | 40 | M | Never | 19del. | 2 | Gefitinib | 100% | 2248 | 978 | 8 | 1 | 1.96 | PD | 33 | 370 |
| 3 | 62 | F | Never | 19del. | 3 | Gefitinib | 0% | 3452 | 434 | 22 | 1 | 1.96 | PD | 51 | 480 |
| 4 | 66 | F | Never | 20 insertion | 4 | None | 30–40% | 5567 | 1405 | 874 | 1 | 1.51 | PR | 616 | 616 |
| 5 | 62 | F | Never | 19del. | 2 | Afatinib | 0% | 951 | 1117 | 508 | 1 | 2.13 | PD | 51 | 355 |
| 6 | 72 | M | Former | 19del. | 2 | Afatinib | 0% | 1548 | 236 | 227 | 1 | 2.17 | PD | 47 | 299 |
| 7 | 62 | F | Never | L858R +T790M | 3 | Afatinib | 5–9% | 1502 | 373 | 11 | 0 | 9.875 | NE | 31 | 361 |
| 8 | 40 | M | Former | S768I | 2 | None | 0% | 1942 | 1186 | 22 | 0 | 4.94 | PD | 7 | 44 |
| 9 | 62 | F | Never | 19del. | 1 | Afatinib | 1–4% | 1407 | 309 | 54 | 1 | 3.44 | PD | 31 | 230 |
F, female; M, male; G, gefitinib; E, erlotinib; A, afatinib; PS, performancde status; NLR, netrophil to lymphocyte ratio; PFS, progression-free survival; OS, overall survival